IOL Myopia, Hyperopia Studies Should Include 3-Year Follow Up - FDA Panel
This article was originally published in The Gray Sheet
Intraocular lens manufacturers pursuing approval for myopia and hyperopia indications should conduct 550-patient studies with three-year follow up, FDA's Ophthalmic Devices Advisory Panel concluded at an Oct. 23 meeting in Silver Spring, Maryland.
You may also be interested in...
Refractive implant manufacturers pursuing claims for device implantation in phakic eyes - those with a natural lens - should conduct separate studies on younger and older patient populations to examine the risk of cataractogenesis, FDA's Ophthalmic Devices Advisory Panel recommended at a May 12 meeting.
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.